{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:44:12Z","timestamp":1781833452853,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejca.2020.09.034","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T16:23:53Z","timestamp":1604075033000},"page":"115-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Identification of nephronectin as a new target for IGF1 action"],"prefix":"10.1016","volume":"141","author":[{"given":"Rive","family":"Sarfstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Lapkina-Gendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Nagaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Laron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0154-1290","authenticated-orcid":false,"given":"Haim","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.09.034_bib1","first-page":"825","article-title":"A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in\u00a0vitro","volume":"49","author":"Salmon","year":"1957","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.ejca.2020.09.034_bib2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ncpendmet0427","article-title":"Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor-1","volume":"3","author":"LeRoith","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metabol"},{"key":"10.1016\/j.ejca.2020.09.034_bib3","first-page":"11","article-title":"Metabolic effects of IGF-I deficiency: lessons from mouse models","volume":"3","author":"Yakar","year":"2005","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.ejca.2020.09.034_bib4","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1210\/me.2014-1174","article-title":"Human GH receptor-IGF-1 receptor interaction: implications for GH signaling","volume":"28","author":"Gan","year":"2014","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ejca.2020.09.034_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tem.2008.03.003","article-title":"IGF signaling defects as causes of growth failure and IUGR","volume":"19","author":"Klammt","year":"2008","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.ejca.2020.09.034_bib6","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1210\/endo.141.7.7586","article-title":"Assessment of growth parameters and life span of GHR\/BP gene-disrupted mice","volume":"141","author":"Coschigano","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejca.2020.09.034_bib7","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1073\/pnas.0705467105","article-title":"Functionally significant insulin-like growth factor I receptor mutations in centenarians","volume":"105","author":"Suh","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2020.09.034_bib8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.mrrev.2016.08.002","article-title":"IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome","volume":"772","author":"Laron","year":"2017","journal-title":"Mutat Res Rev Mutat Res"},{"key":"10.1016\/j.ejca.2020.09.034_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-8-2","article-title":"Basic and clinical significance of IGF-1-induced signatures in cancer","volume":"8","author":"Werner","year":"2010","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2020.09.034_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0065-230X(08)60354-1","article-title":"The role of the insulin-like growth factor system in human cancer","volume":"68","author":"Werner","year":"1996","journal-title":"Adv Canc Res"},{"key":"10.1016\/j.ejca.2020.09.034_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/er.2018-00166","article-title":"Growth hormone's links to cancer","volume":"40","author":"Boguszewski","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejca.2020.09.034_bib12","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1073\/pnas.89.9.3889","article-title":"Ras proteins are essential and selective for the action of insulin-like growth factor 1 late in the G1 phase of the cell cycle in BALB\/c murine fibroblasts","volume":"89","author":"Lu","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2020.09.034_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/ijc.11487","article-title":"The IGF-1 receptor in cancer biology","volume":"107","author":"Baserga","year":"2003","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.09.034_bib14","first-page":"2463","article-title":"The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo","volume":"55","author":"Resnicoff","year":"1995","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2020.09.034_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ghir.2014.03.006","article-title":"Transcriptional and epigenetic control of IGF1R gene expression: implications in metabolism and cancer","volume":"24","author":"Werner","year":"2014","journal-title":"Growth Hormone IGF Res"},{"key":"10.1016\/j.ejca.2020.09.034_bib16","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/onc.2011.447","article-title":"Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer","volume":"31","author":"Werner","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2020.09.034_bib17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/er.2006-0001","article-title":"The role of the IGF system in cancer growth and metastasis: overview and recent insights","volume":"28","author":"Samani","year":"2007","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejca.2020.09.034_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study","volume":"279","author":"Chan","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejca.2020.09.034_bib19","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","article-title":"Circulating concentrations of insulin-like growth factor-I and risk of breast cancer","volume":"351","author":"Hankinson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.09.034_bib20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0140-6736(04)16044-3","article-title":"Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis","volume":"363","author":"Renehan","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2020.09.034_bib21","first-page":"231","article-title":"Natural history of the classical form of primary growth hormone resistance (Laron syndrome)","volume":"12","author":"Laron","year":"1999","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.ejca.2020.09.034_bib22","series-title":"Laron syndrome - from man to mouse","author":"Laron","year":"2011"},{"key":"10.1016\/j.ejca.2020.09.034_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ghir.2015.08.001","article-title":"A half-century of studies of growth hormone insensitivity\/Laron syndrome: a historical perspective","volume":"28","author":"Rosenbloom","year":"2016","journal-title":"Growth Hormone IGF Res"},{"key":"10.1016\/j.ejca.2020.09.034_bib24","doi-asserted-by":"crossref","first-page":"8083","DOI":"10.1073\/pnas.86.20.8083","article-title":"Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism","volume":"86","author":"Godowski","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2020.09.034_bib25","first-page":"6","article-title":"Fifty years on: new lessons from Laron syndrome","volume":"19","author":"Werner","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ejca.2020.09.034_bib26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1210\/jc.2003-031033","article-title":"Extensive personal experience. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003","volume":"89","author":"Laron","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2020.09.034_bib27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng0597-13","article-title":"A dominant-negative mutation of the growth hormone receptor causes familial short stature","volume":"16","author":"Ayling","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2020.09.034_bib28","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/j.1460-2075.1994.tb06392.x","article-title":"A single amino acid substitution in the exoplasmic domain of the human growth hormone receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization","volume":"13","author":"Duquesnoy","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.ejca.2020.09.034_bib29","first-page":"489","article-title":"Genetic analysis of the pedigrees and molecular defects of the GH-receptor gene in the Israeli cohort of patients with Laron syndrome","volume":"Suppl. 3","author":"Shevah","year":"2006","journal-title":"Pediatr Endocrinol Rev"},{"key":"10.1016\/j.ejca.2020.09.034_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ghir.2006.10.007","article-title":"Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report","volume":"17","author":"Shevah","year":"2007","journal-title":"Growth Hormone IGF Res"},{"key":"10.1016\/j.ejca.2020.09.034_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/EJE-10-0859","article-title":"Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies","volume":"164","author":"Steuerman","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejca.2020.09.034_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001845","article-title":"Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans","volume":"3","author":"Guevara-Aguirre","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2020.09.034_bib33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/ERC-16-0054","article-title":"Identification of signaling pathways associated with cancer protection in Laron syndrome","volume":"23","author":"Lapkina-Gendler","year":"2016","journal-title":"Endocr Relat Canc"},{"key":"10.1016\/j.ejca.2020.09.034_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1083\/jcb.200103069","article-title":"Identification and characterization of a novel extracellular matrix protein nephronectin that is associated with integrin alpha8beta1 in the embryonic kidney","volume":"154","author":"Brandenberger","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ejca.2020.09.034_bib35","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1242\/dev.005033","article-title":"The ECM protein nephronectin promotes kidney development via integrin alpha8beta1-mediated stimulation of Gdnf expression","volume":"134","author":"Linton","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.ejca.2020.09.034_bib36","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/2211-5463.12544","article-title":"Nephronectin mediates p38 MAPK-induced cell viability via its integrin-binding enhancer motif","volume":"8","author":"Toraskar","year":"2018","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ejca.2020.09.034_bib37","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/jcp.26013","article-title":"The emerging role of NPNT in tissue injury repair and bone homeostasis","volume":"233","author":"Sun","year":"2017","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ejca.2020.09.034_bib38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neo.2018.02.008","article-title":"Nephronectin is correlated with poor prognosis in breast cancer and promotes metastasis via its integrin-binding motifs","volume":"20","author":"Steigedal","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejca.2020.09.034_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/1541-7786.1.3.1","article-title":"Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix","volume":"3","author":"Eckhardt","year":"2005","journal-title":"Mol Canc Res"},{"key":"10.1016\/j.ejca.2020.09.034_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1349-7006.2007.00678.x","article-title":"Loss of nephronectin promotes tumor progression in malignant melanoma","volume":"99","author":"Kuphal","year":"2008","journal-title":"Canc Sci"},{"key":"10.1016\/j.ejca.2020.09.034_bib41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G","article-title":"Metastatic sublines of an SV40 large T antigen immortalized human prostate epithelial cell line","volume":"34","author":"Bae","year":"1998","journal-title":"Prostate"},{"key":"10.1016\/j.ejca.2020.09.034_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.ejca.2020.09.034_bib43","doi-asserted-by":"crossref","first-page":"6657","DOI":"10.4081\/tmr.6657","article-title":"Genome-wide profiling of congenital IGF1 deficient patients: translational implications in cancer prevention and metabolism","volume":"1","author":"Werner","year":"2017","journal-title":"Transl Med Rep"},{"key":"10.1016\/j.ejca.2020.09.034_bib44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1530\/EC-13-0086","article-title":"Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells","volume":"3","author":"Weinstein","year":"2014","journal-title":"Endocr Connect"},{"key":"10.1016\/j.ejca.2020.09.034_bib45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ecl.2012.04.008","article-title":"Insulin-like growth factor 1 physiology: lessons from mouse models","volume":"41","author":"Yakar","year":"2012","journal-title":"Endocrinol Metab Clin N Am"},{"key":"10.1016\/j.ejca.2020.09.034_bib46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13813450902783106","article-title":"The insulin-like growth factor-I receptor as an oncogene","volume":"115","author":"Werner","year":"2009","journal-title":"Arch Physiol Biochem"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2020.09.034_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000090642","article-title":"Molecular mechanisms of IGF-I deficiency","volume":"65","author":"Rosenfeld","year":"2006","journal-title":"Horm Res"},{"key":"10.1016\/j.ejca.2020.09.034_bib48","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1210\/jc.2006-1641","article-title":"Controversy in clinical endocrinology: problems with reclassification of insulin-like growth factor I production and action disorders","volume":"91","author":"Cohen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ejca.2020.09.034_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cells8060596","article-title":"Genome-wide profiling of Laron Syndrome patients identifies novel cancer protection pathways","volume":"8","author":"Werner","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2020.09.034_bib50","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1074\/jbc.M112.412536","article-title":"Insulin-like growth factor (IGF) signaling requires \u03b1v\u03b23-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation","volume":"288","author":"Fujita","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2020.09.034_bib51","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1083\/jcb.200106124","article-title":"Mystery solved: discovery of a novel integrin ligand in the developing kidney","volume":"154","author":"Miner","year":"2001","journal-title":"J Cell Biol"},{"key":"10.1016\/j.ejca.2020.09.034_bib52","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12253-017-0289-0","article-title":"Nephronectin is decreased in metastatic breast carcinoma and related to metastatic organs","volume":"24","author":"Dilmac","year":"2018","journal-title":"Pathol Oncol Res"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2021.02.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492031042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492031042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T21:39:58Z","timestamp":1669412398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492031042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":52,"alternative-id":["S095980492031042X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.09.034","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2021.02.014","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of nephronectin as a new target for IGF1 action","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.09.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}